Background. We have shown that acadesine (AICAr: 5-amino-4-imidazole carboxamide riboside) improves the early recovery of function of the ischemic and reperfused rat heart. In the present studies we used the transplanted rat heart, with reperfusion for up to 24 hours, to assess whether the beneficial effect of acadesine is a transient or a sustained phenomenon (i.e., to determine whether the drug improves the extent of recovery or only the rate).
Sustained Protection by Acadesine Against Ischemia-and Reperfusion-Induced Injury utes? 3) Because there is evidence5 that acadesine may exert a beneficial effect upon leukocyte-mediated injury, could the protective effects of acadesine have been limited by our use of hearts that were reperfused with crystalloid media?
In an attempt to answer these questions, we have exploited the heterotopically transplanted rat heart preparation that allows 1) reperfusion with blood after a period of ischemia and 2) the evaluation of functional capability after both short (30 minutes) and extended (24 hours) periods of blood reperfusion. In the present studies, we also considered the mechanisms that possibly may underlie protection; particular attention was given to the extent to which the drug can modify the metabolism of adenine nucleotides during ischemia and reperfusion.
Methods Male homozygous Lewis rats weighing 300-350 g were used. All The experimental preparation and techniques have been previously described in detail. 6 Excision and storage of hearts. Rats (n = 8 per group) were anesthetized with sodium pentobarbital (60 mg/kg i.p.) and mechanically ventilated through a tracheostomy at 55 strokes per minute and at a ventilation pressure of 12-14 mm Hg. The chest was opened, and the venae cavae and pulmonary veins were isolated; sodium heparin was administered (1,000 units/kg i.v.). The venae cavae and pulmonary veins then were ligated, and the heart was excised and placed in cold (4°C) saline. The aorta was rapidly cannulated, and St. Thomas' Hospital cardioplegic solution containing (mmol/l) NaCl 110.0, KCl 16.0, MgCl2 16.0, CaCl2 1.2, and NaHCO3 10.0 (pH 7.8) was immediately infused at a constant pressure of 45 mm Hg for 2 minutes at 20°C. Hearts then were stored for 4 hours at 20°C immersed in the same cardioplegic solution with reinfusion of the solution for 2 minutes every 30 minutes throughout the 4-hour period of hypothermic ischemia. In some study groups, acadesine (20 ,umol/l) was added to the cardioplegic solution.
Transplantation procedure. The abdomen of an anesthetized recipient rat was opened through a midline incision, and the abdominal aorta and inferior vena cava were exposed. The donor heart (which had been stored for 4 hours) was removed from the hypothermic chamber and, with 9-0 Ethicon sutures, the aorta and pulmonary artery were anastomosed (end-to-side) to the abdominal aorta and inferior vena cava, respectively, of the recipient rat. The heart was maintained at 18-22°C during the implantation period; this was achieved by wrapping it in a swab, which was regularly irrigated with cold (6-10°C) saline. To minimize variability between experiments, the duration of the implantation period was standardized at 60 minutes for all studies. Hearts or 24 hours. In some study groups, acadesine (100 mg/ml dissolved in saline) was administered (100 mg/kg i.v.) to the recipient rat 15 minutes before transplantation (i.e., 75 minutes before reperfusion). In other groups, an equivalent volume of saline was administered. When the hearts were reperfused for 24 hours, the abdominal walls of the recipient rats were closed in two layers, and the animals were allowed to recover and then kept for 24 hours in an unrestrained state with normal feeding.
In Vitro Assessment After Transplantation and Reperfusion
Thirty minutes or 24 hours after implantation and reperfusion of the transplanted hearts, recipient rats were again anesthetized, the right femoral vein was exposed, and sodium heparin was administered (100 mg/kg i.v.). The abdomen was reopened and the transplanted heart excised and placed in cold (4°C) saline. The aorta was rapidly cannulated and each heart perfused aerobically at a constant pressure (75 
Study Groups
Eight groups of hearts were studied: four after 30 minutes and four after 24 hours of in situ reperfusion. In both instances, four protocols were used ( Figure 1): group A, acadesine-free control; group B, acadesine (20 ,umol/l) included in the cardioplegic solution only; group C, acadesine (100 mg/kg i.v.) during reperfusion alone (the drug was given to the recipient 15 minutes before transplantation on the assumption that it would be present in the blood during reperfusion of the implanted heart); and group D, acadesine during both cardioplegia (20 .tmol/l) and reperfusion (100 mg/kg i.v. to the recipient, 15 minutes before transplantation).
For comparative purposes, measurements of control function also were made in fresh aerobically perfused, nontransplanted hearts (n=8), which had not been subjected to ischemia. Two additional groups of hearts (n=4 per group) were subjected to ischemia (with and without acadesine added to the cardioplegic solution) and transplantation; these hearts were not reperfused but were taken for metabolite analysis at the end of the 1-hour period of surgical implantation (end-ischemic values). 
Results

Contractile Function (30 Minutes of Reperfusion)
Acadesine-free controls: group A. Before reperfusion, these hearts were subjected to a total of 5 hours of ischemia ( Figure 2 ). The results show that, in comparison with aerobic controls (which had not been made ischemic), acadesine-free controls (which had been subjected to 4 hours of hypothermic storage, transplantation, and reperfusion) had suffered a substantial deterioration of function when assessed after 30 The results in Table 1 show that nonischemic aerobic controls had a high ATP content and low contents of IMP, AMP, and ADP. The levels of inosine and adenosine were below the limit of detection. At the end of 4-hour storage and 1-hour transplantation (without reperfusion; i.e., 5 hours of ischemia), there was considerable depletion of ATP (from 20.8±1.4 ,.tmol/g dry wt in fresh aerobic control hearts to 1.4±0.2 ,tmol/g dry wt in the acadesine-free group) and ADP and substantial increases in IMP and AMP. Inosine and adenosine were detected in high concentrations. The adenylate pool and ECP were also greatly reduced. Acadesine, given as an additive during the multidose cardioplegia, resulted in a significant increase in the end-ischemic values for tissue content of adenosine (from 2.93±0.26 to 4.16±0.34 j.Lmol/g dry wt; p<0.05) and a significantly higher level of ATP (3.4±0.6 versus 1.4± 0.2 gmol/g dry wt). As a consequence, the ECP was higher in the acadesine-treated group. The mean IMP content of the hearts at the end of the ischemic period tended to be attenuated in the acadesine-treated group; however, this difference failed to achieve a level of statistical significance.
After 30 minutes of reperfusion, the acadesine-free controls showed a substantial repletion of the nucleotide pool (ATP content increased to 11.2±0. 6 ,umol/g dry wt) and normalization of the ECP. Reperfusion also reduced IMP content to near its aerobic control value. The inclusion of acadesine in the cardioplegic solution resulted in a significantly higher IMP value (0.22+0.03 1£mol/g dry wt) than in the acadesine-free group (0.07+±0.01 ,.mol/g dry wt) or the fresh aerobic control group (0.02+0.01 ,imol/g dry wt). Acadesine given during reperfusion did not influence the recovery of the adenylate pool. The administration of acadesine during both cardioplegia and reperfusion, however, resulted in a higher content of IMP (0.25 +0.03 ,mol/g dry wt) and further improvement in ATP content (14.7+1.0 ,.mol/g dry wt).
Contractile Function (24 Hours of Reperfusion) Acadesine-free controls: group A. The results show that, after 24-hour reperfusion, the acadesine-free controls had suffered a sustained and substantial deterioration of function, which was even greater than that observed after 30-minute reperfusion (Figure 3) After 24 hours of reperfusion in the acadesine-free group and in all the acadesine-treated groups, the content of IMP fell within the normal range, and ATP and the adenylate pool increased to a greater extent than in the corresponding 30-minute group. Therefore, the adenine nucleotide pool was returned almost completely to normal after 24 hours of reperfusion (Table 1) . Discussion In the present investigation, we have used the heterotopically transplanted rat heart to study the effects of acadesine in a blood-reperfused preparation during brief (<1 hour) and extended (24 hours) periods of reperfusion. In addition to providing the advantages of a bloodreperfused model, this preparation allows us to distinguish between the ability of an intervention to increase ultimate extent of recovery as opposed to increasing the rate of recovery (i.e., overcoming myocardial stunning). The model also permits the dissociation of protective effects, which are manifest immediately upon reperfusion from those that develop over a longer period.
Using this model, we conclude that acadesine, when used solely as an additive to a cardioplegic solution, affords an immediate and sustained improvement in the postischemic recovery of function. It is important to stress that when used in this fashion, little or no acadesine is present in the blood during reperfusion. The only acadesine to enter the circulation is the small quantity that is trapped in the vasculature (or is taken up by the tissue) during the period of ex vivo hypothermic ischemic storage and is washed out at the moment cardioplegic component of acadesine protection almost certainly operates during ischemia and, perhaps, the first few seconds of reperfusion. Evidence against an effect during early reperfusion is provided by the part of our studies in which acadesine was present during reperfusion alone but afforded no protection during the early phase of recovery. In this reperfusion-alone group, however, substantial protection was obtained during the later stages of reperfusion, which suggests the existence of a second-and later-acting component to acadesine protection.
Although our demonstration of a protective effect of acadesine is supported by Mitsos et al,2 there are conflicting studies.12-'4 As discussed previously,' we believe that several factors, including the duration of ischemia, the time of administration, and the dose, may be important in determining the efficacy of acadesine.
Prevention of Ischemia-and Early Reperfusion-Induced Injury: First Component of Acadesine Protection
The improvement in the recovery of cardiac function early during reperfusion obtained in the present studies, in which hearts were reperfused with whole blood, further support the findings of our previous study,' in which reperfusion was carried out with crystalloid media. In both cases, acadesine was similarly protective, whether given before or during ischemia. In neither case did the drug have any effect upon the early recovery of function when it was given only during reperfusion. In view of this similarity of results and the absence of leukocytes from the crystalloid perfused preparation, it could be argued that the protective effects of acadesine, expressed during early reperfusion, are unlikely to be mediated through an effect upon leukocyte activity or plugging. In further support of this argument, we have been unable, in other studies (unpublished data) with transplanted rat hearts, to demonstrate leukocyte infiltration after 1, 4, or 24 hours of reperfusion. It could, of course, be argued that the degree of ischemic injury inflicted in our model is insufficient to trigger an inflamatory response. Therefore, it may well transpire that in ischemia-reperfusion models with more severe injury, in which there is accumulation of leukocytes,15 acadesine may exert some additional beneficial effect. In this connection, Gruber et a15 have shown that acadesine, administered before and during 1 hour of regional ischemia in the dog heart, decreases the accumulation of granulocytes and improves the collateral flow to the ischemic myocardium.
In addition to leukocytes, a variety of factors have been suggested as contributing to the induction of injury during ischemia and reperfusion. These include disturbances of ionic homeostasis,16'7 the depletion of highenergy phosphates,18 the denaturation of cell constituents,19 and the production of free radicals.4"19 The results of the present study might suggest that acadesine may act, at least in part, by slowing the ischemiainduced depletion of the adenine nucleotide pool. In the acadesine group, the tissue ATP content was higher than in the control group at the end of ischemia as was the ECP. Acadesine tended to attenuate the ischemiainduced accumulation of IMP and resulted in a signifi- In the present studies, multidose acadesine-containing cardioplegia produced a significant increase in the tissue content of adenosine at the end of the ischemic period. This contrasts with the results of our previous studies1 in which we used acadesine either as an additive to single-dose cardioplegia or as a pretreatment. It is possible that frequent administration of acadesine during ischemia is necessary if adenosine is to accumulate in the tissue. This conclusion is supported by the findings of Gruber et al,5 who studied regional ischemia in the dog and showed that the administration of acadesine before and during ischemia increased the concentration of adenosine in coronary sinus blood. The many favorable effects attributed to the administration of adenosine during ischemia and reperfusion22-25 or to the potentiation of its endogenous production26-30 suggest that the beneficial effects of acadesine may in part be caused by the enhancement of tissue adenosine content. It is of interest to note that despite multiple infusions of cardioplegia ( Another factor associated with the treatment with acadesine is its effect on tissue IMP content. This was increased over 100-fold by ischemia, which is a rise that tended to be attenuated when acadesine was present.
Upon early reperfusion, however, the content was consistently higher in the acadesine-treated groups, but after 24 hours of reperfusion it had fallen to within the aerobic control range. Similar changes in the content of IMP have been reported by others14,21,31 after the infusion of acadesine in both ischemic21 and nonischemic143' canine hearts. Such an effect may arise from the conversion of acadesine to IMP20 or from some effect on the regulation of endogenous IMP metabolism. It is of interest that acadesine monophosphate may inhibit adenylosuccinate lyase,3' the enzyme that catalyses the metabolism of IMP to AMP; however, this possibility has been challenged.2' Although it is conceivable that IMP may serve as a precursor in the replenishment of the nucleotide pool or in the production of adenosine, the mechanism of its formation and its putative role in acadesine-mediated protection remains to be elucidated. It is noteworthy that in the setting in which adenosine was elevated, IMP was not (Table 1) . Moreover, Ambrosio et a132 found that acadesine administered at reperfusion increased IMP levels by 20- fold but had no effect on ATP or "free" ADP concentrations.
Because acadesine exerts its protective effects at micromolar doses, it could be argued that it is more likely to act at an inhibitory or regulatory site instead of by the simple provision of adenine nucleotide precursor molecules. Gruber et a15 have shown that acadesine increases the concentration of adenosine only under conditions in which ATP is broken down. They also have suggested that the effects of acadesine are not mediated via inhibition of adenosine degradation or its uptake by blood cells. Because Gruber et al found that the adenosine-to-inosine ratio in the coronary venous blood was increased during ischemia when acadesine was administered, they suggested that the catabolic pathways for ATP are in some way altered by the drug.
In this connection, it has been suggested that acadesine might inhibit or stimulate specific enzymes533 associated with the metabolism of nucleotides and nucleosides and, therefore, lead to an increase in tissue adenosine levels. At the present time, however, the exact mechanism by which acadesine increases adenosine levels remains unknown.
Prevention of Late Reperfusion-Induced Injury: Second Component ofAcadesine Protection
The observation that acadesine, when administered during reperfusion alone, had no effect on early postischemic recovery of function but was found to be efficacious when recovery was assessed 24 hours later, is of considerable interest and possibly suggests that the drug has some action against unfavorable effects occurring later in the reperfusion period. These results are partially supported by Ambrosio et al,32 who have shown that the administration of acadesine during the reperfusion period in the isolated rabbit heart does not improve the early recovery of function. These authors, however, did not extend the reperfusion period further than 2 hours, and a possible late effect of acadesine was not investigated. The possibility of late reperfusioninduced injury has been considered by a number of authors.3435 Bolli et al3637 have shown the continuing protection afforded by free radical scavengers long into the reperfusion period. Other authors34,35 have studied the delayed or slow no-reflow phenomenon, and Przyklenk et a138 have shown that nifedipine administered 30 minutes after the onset of reperfusion can exert beneficial effects in the canine myocardium. Events such as neutrophil accumulation and capillary plugging are believed to occur relatively late during the reperfusion process,39 and this raises the possibility that acadesine may act by counteracting some of the late reperfusion events, which possibly includes leukocyte infiltration. Although the inhibition of leukocyte plugging would provide an attractive mechanism of action for acadesine, it is important to restate the results of our preliminary study of leukocyte infiltration. Using the same experimental model as that used in the present study, we have shown that, after a similar period of ischemia and 24 hours of reperfusion, no leukocyte accumulation can be detected (unpublished data). Furthermore, although leukocyte depletion improved the early recovery of function in these studies, any benefit was lost after 24 hours of reperfusion. Therefore, we conclude that an effect upon leukocytes is unlikely to be the main factor explaining the protection afforded by acadesine during the late reperfusion phase.
The sustained protective effect of acadesine cannot be explained simply by a faster or greater recovery of the adenine nucleotide pool because after 24 hours this was almost completely replenished whether or not the drug was administered. The almost complete replenishment of the adenine nucleotide pool after 24 hours of reperfusion would lend further support to our earlier argument that there is no necrosis in the transplanted hearts after 24 hours of reperfusion. If this is the case, then it could be argued that acadesine is acting primarily by accelerating the rate of recovery (i.e., overcoming myocardial stunning) instead of increasing the absolute extent of recovery. If this is the case, then a full recovery of function would be expected to require more than 24 hours of reperfusion.
It is interesting to note that, although the plasma half-life of acadesine in the rat is only 15 minutes,9 the drug was able to provide protection after 24 hours. A possible explanation may lie in the findings of Dixon et al,10 who have shown in human beings that acadesine can accumulate in red blood cells as its 5'-monophosphate metabolite, which has a half-life in blood of 2-3 days. High concentrations of the nucleotide also have been shown to accumulate in the heart and liver of rats. 9 Therefore, it appears that the plasma concentration of the nucleoside may not reflect intracellular concentrations, which might in some way continue to contribute to its therapeutic efficacy.
Limitations of Heterotopic Transplantation Model
The opportunity to study the recovery of the globally ischemic heart over a 24-hour period of reperfusion with blood offers obvious advantages over the majority of isolated preparations of cardiac global ischemia in which reperfusion is carried out with crystalloid solutions (or blood) for relatively short periods of time. The heterotopic transplant model, however, has certain limitations that should be recognized. In particular, the heart is denervated and unloaded, and, as we and others have shown,640 this will lead to a time-dependent mechanical deterioration and atrophy. Nevertheless, in detailed characterization studies6 with this model, we have shown that major deterioration does not occur until at least 24 hours after implantation. In the present study, we cannot exclude the possibility that such factors may have influenced our results to some degree.
Conclusions
The present studies have demonstrated that 1) acadesine, used as an additive to multidose cardioplegia, leads to increases in the adenine nucleotide and adenosine contents in tissue at the end of ischemia and improves the postischemic content of ATP and contractile function and that this protection is sustained for at least the first 24 hours of reperfusion; 2) acadesine, when administered during reperfusion, has no effect on the early metabolic or functional recovery of the heart; however, after 24 hours it results in improved functional recovery to an extent similar to that observed when acadesine was administered during cardioplegia alone; and 3) acadesine, used during both cardioplegia and reperfusion, results in an accelerated metabolic recovery and sustained functional improvement. The mechanisms underlying the protective properties of acadesine remain to be resolved. They are likely to involve processes that are operative during ischemia and also during the later phases of the reperfusion process. Protective effects on adenine nucleotide metabolism and adenosine content may play a part, and present evidence indicates that at least two components are involved in protection.
